- Advertisement -
- Advertisement -
- Advertisement -

Find a job

Subscribe for free

All things Pharma

Javlor no-go for bladder cancer

 Pierre-Fabre’s Javlor (vinflunine) has not been recommended for the treatment of advanced or metastatic transitional cell carcinoma in final draft guidance.

NICE says that supplied data failed to show how effective the drug is against best supportive care and also raised concerns that its negative side effects were not addressed.

Sir Andrew Dillon, NICE Chief Executive, said that Pierre-Fabre was unable to provide “conclusive evidence” on issues raised by its Appraisal Committee.

Patients currently receiving Javlor now have the option to continue therapy until they and their clinicians consider it appropriate to stop.

Commenting on the draft guidance, Sir Andrew Dillon says that the Institute has to be fully convinced when recommending expensive cancer treatments.

“When we recommend the use of expensive treatments designed to extend life, we need to be confident about the nature and the extent of the benefit they bring,” he said.

“In the case of vinflunine, the manufacturer has been unable to provide the committee with conclusive evidence on how effective vinflunine is, particularly the extent to which it can prolong survival compared with best supportive care.

“The committee also had concerns that the negative side effects of vinflunine, such as severe constipation, were not fully taken account of in the economic evaluation.”

- Advertisement -

MORE FROM AUTHOR

- Advertisement -

LATEST POSTS

Subscribe

Sign up to receive our digital newsletter, for all the essential headlines, Jobs of the Week and thought-provoking features.

Claim my free subscription